Innovation gives Chinese biopharma edge on global stage

Tie-ups helping companies expand influence, market coverage

Innovative domestic biopharmaceutical companies are beginning to bring their research and development results beyond China after at least 15 years of accumulating experience in new drug development and carrying out clinical trials, industry experts said.

Such high-speed growth of Chinese medical research results will stay on pace for another decade before entering a stabilization phase, they said.

Recent examples include a new drug application for an innovative drug to treat neuroendocrine tumors developed by Hutchison China MediTech－or Hutchmed－which was submitted to the United States Food and Drug Administration. Its market application in Europe is underway.